Amyvid radiopharmaceutical ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04390009 (ClinicalTrials.gov) | September 1, 2022 | 12/5/2020 | Entire-body PET Scans for Multiple Sclerosis | Exploratory Study of Entire-body PET Scans for Multiple Sclerosis | Multiple Sclerosis | Diagnostic Test: Entire-body PET-CT scans;Drug: Amyvid radiopharmaceutical | Brain Health Alliance | NULL | Recruiting | 25 Years | 55 Years | All | 20 | Early Phase 1 | United States |